Bio Rad Laboratories Inc

Stage 2 advance with a momentum breakout and HH/HL regime establishes medium-term bullish asymmetry, but price is extended above rising EMAs and overbought on RSI. Timing favors deferred entry on shallow pullbacks into the 9/21 EMA support zone or retest of recent consolidation highs, while the long-term downtrend remains a moderating factor.

• ↑Digital PCR revenue +24% YoY, strong market reception for QX700.
• ↑Clinical diagnostics sales $364M in Q1 up 1.9%, gross margin stable at 52.3%.
• ↓2026 EPS guidance cut to $9.30 from $9.42 (–1.3%), signaling earnings pressure.